Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer
The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide prostate cancer treatment, featuring talazoparib (...
Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable Healthcare
Sandoz's Strategic Momentum in Biosimilars and Generics
Sandoz's biosimilars strategy, as highlighted during the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, outlines its prog...
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
Pioneering Alzheimer's Care Innovation in Europe
Alzheimer's care innovation is transforming Europe's approach to the disease, shifting from policy discussions to real-world implementation of disease-modifying therapies. With 10 milli...